Clinical trial
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
NCT02785952 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)
- Lead sponsor
- SWOG Cancer Research Network
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- December 29, 2015
- Completion date
- April 1, 2027
- Enrollment
- 275 (actual)
- Sites
- 1,207
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent squamous cell lung carcinoma, stage iv squamous cell lung carcinoma ajcc v7